Aktieanalys

BioInvent Q2 2024: Positive Development with BI-1206 and BI-1808 - Redeye

{newsItem.title}

Redeye Publicerad: 30 Aug 12:08

Redeye comments on BioInvent's Q2 report 2024. Positive new results from BI-1206 in lymphoma and solid tumours and from BI-1808 were presented during the quarter.

Länk till analysen i sin helhet: https://www.redeye.se/research/1037425/bioinvent-q2-2024-positive-development-with-bi-1206-and-bi-1808?utm_source=finwire&utm_medium=RSS

Nyheter om Bioinvent

Läses av andra just nu

Om aktien Bioinvent

Senaste nytt